These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prostate cancer immunotherapy. May KF; Gulley JL; Drake CG; Dranoff G; Kantoff PW Clin Cancer Res; 2011 Aug; 17(16):5233-8. PubMed ID: 21700764 [TBL] [Abstract][Full Text] [Related]
4. The evolving role of immunotherapy in prostate cancer. Gerritsen WR Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924 [TBL] [Abstract][Full Text] [Related]
5. Combining immunotherapies for the treatment of prostate cancer. Redman JM; Gulley JL; Madan RA Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441 [TBL] [Abstract][Full Text] [Related]
6. Sipuleucel-T and immunotherapy in the treatment of prostate cancer. Dawson NA; Roesch EE Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782 [TBL] [Abstract][Full Text] [Related]
7. Current status of immunological approaches for the treatment of prostate cancer. Drake CG; Antonarakis ES Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018 [TBL] [Abstract][Full Text] [Related]
8. A New Era of Immunotherapy in Prostate Cancer. Pizzola C; Rizvi SM; Joshi M Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in immunotherapy for the treatment of prostate cancer. Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925 [TBL] [Abstract][Full Text] [Related]
10. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks. Comiskey MC; Dallos MC; Drake CG Curr Oncol Rep; 2018 Aug; 20(9):75. PubMed ID: 30120592 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic vaccines for prostate cancer. Cha E; Fong L Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819 [TBL] [Abstract][Full Text] [Related]
14. Molecular insights into the development of T cell-based immunotherapy for prostate cancer. Dong B; Minze LJ; Xue W; Chen W Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804 [TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy: sipuleucel-T and beyond. Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg? Laccetti AL; Subudhi SK Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in prostate cancer: review of the current evidence. Fernández-García EM; Vera-Badillo FE; Perez-Valderrama B; Matos-Pita AS; Duran I Clin Transl Oncol; 2015 May; 17(5):339-57. PubMed ID: 25480118 [TBL] [Abstract][Full Text] [Related]
18. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Antonarakis ES; Drake CG Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic vaccines for prostate cancer: recent advances and future directions. Strauss J; Madan RA Expert Rev Vaccines; 2016 Jul; 15(7):907-14. PubMed ID: 26889831 [TBL] [Abstract][Full Text] [Related]
20. The current and emerging role of immunotherapy in prostate cancer. Madan RA; Gulley JL Clin Genitourin Cancer; 2010 Dec; 8(1):10-6. PubMed ID: 21208850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]